Request A Demo

Competitive Landscape - Breast Imaging

The only platform that sees tissue function, not just anatomy.

Every major breast ultrasound platform on the market today layers AI onto grayscale or Doppler anatomy. Imagio® Breast Imaging System is the only FDA PMA‑approved system that adds real functional, physiologic data — visualizing tissue hypoxia tied to tumor angiogenesis — to guide diagnosis.

Imagio® Breast Imaging System GE HealthCare Philips Canon Medical United Imaging Samsung
Functional Imaging ✓ Laser‑optoacoustic + US functional data × Anatomical 3D US only ~ Doppler / elastography ~ Microvascular flow (SMI) × Anatomical only ~ Doppler / elastography
Opto-Acoustic Imaging ✓ FDA PMA‑approved (P200003) × Not offered × Not offered × Not offered × Not offered × Not offered
Visualizes Tissue Hypoxia ✓ Deoxygenated & Oxygenated blood / angiogenesis × Not possible × Not possible × Not possible × Not possible × Not possible
AI Decision Support ✓ Built on functional + anatomic data ✓ QView CAD, scan quality AI ~ Limited on US ~Limited breast CAD ~Emerging, not breast‑specific ✓ S‑Detect AI‑CAD
Breast Cancer Diagnosis ✓ Improved Diagnostic workup, Benign biopsy reduction ~ Supplemental screening (dense breast) ~ General‑purpose breast US ~ General‑purpose breast US ~ General‑purpose, not specialized ~ Screening/diagnostic aid via CAD

DIFFERENTIATOR

Zero major competitors offer opto-acoustic imaging or hypoxia visualization. GE, Philips, Canon, United Imaging, and Samsung all build their AI story on top of conventional grayscale or Doppler anatomy. Imagio® is the only platform pairing AI decision support with real functional, physiologic tissue data — not just structure.

Imagio® OA/US is FDA PMA‑approved (P200003). Competitor capabilities reflect publicly available product information as of Aug 2026 and are for internal comparison purposes only; verify current claims against each manufacturer’s official specifications before external use.